Linaclotide is a small, tightly knotted peptide that draws fluid into the intestine. It treats constipation-type gut disorders by acting on a receptor in the gut lining. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and boxed warning, with sources checked on November 17, 2026.
Quick answer: Linaclotide is a prescription guanylate cyclase-C agonist. Its label covers irritable bowel syndrome with constipation, chronic idiopathic constipation, and pediatric functional constipation. It carries a boxed warning for serious dehydration in children under 2. Diarrhea is its main side effect.
Vitrapep does not sell linaclotide; this page is a reference summary of published research and regulatory information.
What is linaclotide?
Linaclotide is a guanylate cyclase-C agonist peptide. DrugBank text in PubChem calls it “a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.” ChEBI says it is “cyclised by three disulfide bonds” between cysteines 1 and 6, 2 and 10, and 5 and 13 (PubChem CID 16158208).
It counts as a peptide because it is a short chain of amino acids. The three disulfide bridges lock that chain into a folded, ring-like shape. DrugBank notes it is “structurally related to human guanylin and uroguanylin,” two natural gut peptides. It is “also a homolog of a heat-stable enterotoxin derived from Escherichia coli.” PubChem lists the formula as C59H79N15O21S6 and the molecular weight as 1,526.8 g/mol. For how cyclic peptides differ from linear ones, see types of peptides.
Drugs@FDA lists the original approval of Linzess (NDA 202811) on August 30, 2012. AbbVie is the current applicant (Drugs@FDA).
Linaclotide: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic 14-amino-acid peptide with three disulfide bonds |
| Class | Guanylate cyclase-C agonist |
| Molecular formula | C59H79N15O21S6 |
| Molecular weight | 1,526.8 g/mol |
| First FDA approval | August 30, 2012 (Linzess, NDA 202811) |
| Brand names (US) | Linzess |
How does linaclotide work?
The cells lining the intestine carry a receptor called guanylate cyclase-C (GC-C). The Linzess label states that linaclotide binds GC-C on the luminal surface of the intestinal epithelium. That is the inner surface facing the gut contents. The NCI Thesaurus notes that linaclotide “is minimally absorbed from the GI tract,” so it acts locally.
Activating GC-C raises levels of cyclic guanosine monophosphate (cGMP), both inside and outside the cells. Inside, cGMP switches on the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel. Chloride and bicarbonate flow into the gut. The label says this increases intestinal fluid and speeds transit (Linzess label, 2026).
The label also reports animal data on pain. In an animal model of visceral pain, linaclotide “reduced abdominal muscle contraction.” It also decreased the activity of pain-sensing nerves, an effect linked to extracellular cGMP. These findings are from animals, not people.
What is linaclotide approved for?
The Linzess label lists three indications:
- “irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older”;
- “chronic idiopathic constipation (CIC) in adults”; and
- “functional constipation (FC) in pediatric patients 2 years of age and older.”
The label’s Recent Major Changes section dates its indications update to May 2026.
What did the key trials show?
Chronic constipation. Two 12-week, randomized, placebo-controlled trials enrolled 1,276 adults. A responder had at least three complete spontaneous bowel movements a week, plus at least one more than baseline, for 9 of 12 weeks. In Trial 303, 19.4% to 21.2% of linaclotide patients responded, versus 3.3% on placebo. In Trial 01, the figures were 16.0% to 21.3% versus 6.0% (P < 0.01 for all comparisons) (Lembo et al., 2011; NCT00765882; NCT00730015).
IBS-C, 26 weeks. This double-blind trial evaluated 804 adults. The FDA end point needed at least 30% less worst abdominal pain plus one more complete bowel movement. Both had to occur in the same week, for 6 of 12 weeks. Responders were 33.7% with linaclotide and 13.9% with placebo (P < 0.0001) (Chey et al., 2012).
IBS-C, 12 weeks plus withdrawal. This trial randomized 800 adults and then tested a 4-week randomized withdrawal. On the FDA end point, 33.6% responded with linaclotide and 21.0% with placebo (P < 0.0001) (Rao et al., 2012). All three studies were in humans.
What side effects does the label list?
Linzess carries a boxed warning: “Risk of serious dehydration in pediatric patients less than 2 years of age.” The label states that Linzess is contraindicated in patients under 2. In neonatal mice, a single clinically relevant adult exposure to linaclotide caused deaths due to dehydration. This is animal evidence, and it drives the age limit.
The label’s two warnings cover that dehydration risk and diarrhea. In adults with IBS-C or CIC, the most common adverse reactions (2% or more) are diarrhea, abdominal pain, flatulence and abdominal distension. In children with IBS-C or functional constipation, the most common was diarrhea.
What is linaclotide’s regulatory status, and how is it used in research?
Linaclotide is a prescription drug. Drugs@FDA lists Linzess as a current prescription product from AbbVie. DailyMed shows the Linzess label revised in October 2026, with the indications change dated May 2026.
The research summarized here is human clinical trials, plus animal studies of visceral pain cited in the label. A close relative, plecanatide, works the same way; see our plecanatide guide.
Frequently asked questions about linaclotide
Is linaclotide a peptide?
Yes. It is a cyclic peptide of 14 amino acids, held together by three disulfide bonds.
How is linaclotide different from plecanatide?
Both are GC-C agonist peptides. Linaclotide has 14 amino acids and three disulfide bonds. Plecanatide has 16 amino acids, two disulfide bonds and closely resembles uroguanylin.
Why does linaclotide have a boxed warning?
In neonatal mice, a single exposure caused deaths from dehydration. The label contraindicates Linzess in patients under 2.
When was linaclotide approved?
FDA approved Linzess on August 30, 2012.
What is the most common side effect?
Diarrhea. It is listed first among the common adverse reactions in adults and is the most common in children.
What to know now
- Structure: cyclic 14-amino-acid peptide; three disulfide bonds; 1,526.8 g/mol.
- Mechanism: GC-C agonist; raises cGMP and drives chloride and bicarbonate secretion via CFTR.
- Approval: Linzess, August 30, 2012; prescription only.
- Uses: IBS-C (adults, children 7+), CIC (adults), functional constipation (children 2+).
- Evidence: 33.7% vs 13.9% responders in a 26-week IBS-C trial.
- Safety: boxed warning for dehydration in children under 2; diarrhea most common.
What we’re watching
Follow-up on the May 2026 label change that added functional constipation in children 2 years and older. Further Linzess label revisions on DailyMed. Related guides: plecanatide and teduglutide.